Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Mateon Therapeutics — Investor Presentation (September 2019)
27 slides from Oncotelic Therapeutics's investor presentation, Sep 3, 2019
Slide 1: Deploying Immunosurveillance against Cancer: TGF-B RNA Therapeutics
Pp XP Ze ae oy ONCOTELIC Deploying Immunosurveillance against Cancer TGF-B RNA THERAPEUTICS
Slide 2: Forward-looking Statements
nN af? ONCOTELIC® @i y Forward-looking Statements This document contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical
Slide 3: Cancer - Current Landscape
st ONCOTELIC @ Cancer- Current Landscape @ In 2015- cancer death increased globally to 8.8 million of the 55.8 million deaths- or 1 of every 6 deaths. @ In 2035- cancer death and new cases are projected to be 14.6 million and 24 million respectively. AACR Cancer Progress Report 2018 @ Although the r
Slide 4: OT-101 lifts immunosuppression and primes innate immunity
af? ONCOTELIC~ TGF-8 inhibitor (i.e. OT-101) lifts the immunosuppression and primes the innate immunity against the tumor. Once the body recognizes the cancer as foreign everything else is easy. Subsequent chemotherapy boosts the immune response with epitope expansion due to neoantigens released dur
Slide 5: Optimal Sequencing for TGF-B Self Immunization Protocol
BPZ ONCOTELIC Optimal Sequencing for TGF-B Self Immunization Protocol 1. Proper Sequencing is key to optimal immunotherapy 2. Expand immune reserve through IL-2 treatment or infusion of immune cells 3. Prime immune response with TGF-B inhibitor- OT-101 Boost immune response with chemotherapy Revital
Slide 6: OT-101: Drug Product - TGF-B2 Antisense
af? ONCOTELIC~ OT-101: Drug Product- TGF-B2 Antisense. Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-B2 messenger RNA Ready for registration trials--Over 200 patients treated across 6 clinical trials Potential for breakthro
Slide 7: Single Agent Activity - Glioblastoma
af? ONCOTELIC~ (TT y Single Agent Activity- Glioblastoma: @ G004-Phase 2b trial @ Title: A multi-national, multi-center, open-label, active-controlled, randomized parallel-group dose-finding study to evaluate the efficacy and safety of two doses of OT-101 in adult patients with recurrent high-grade
Slide 8: Clinical Efficacy: Objective Responses
ONCOTELIC ~ {11 ) Clinical Efficacy: Objective Responses @ Objective responses were observed among the 87 evaluable patients treated with OT-101: @ Best Objective Responses were: 5 CR (5.9%), 14 PR (16.5%), 28 SD (31.8%), and 40 PD (45.9%) @ Confirmed Best Objective Responses were: 4 CR (4.7%), 12 P
Slide 9: Single Agent Activity - Pancreatic Cancer
af? ONcOTELIC @ ) Single Agent Activity- Pancreatic Cancer @ P001- Phase 1/2 Clinical Trial @ Title: An Open-Label, Multicenter Dose-escalation Study to Evaluate the Safety and Tolerability of OT-101 (TGF- B2-specific Phosphorothioate Antisense Oligodeoxynucleotide), Administered Intravenously in Ad
Slide 10: P001 Phase 1/2 Trial
— tat HM} PO01 Phase 1/2 Trial af? ONCOTELIC~ Pd @ Patient 1006: CR as far out as 77 mos & z Fe 3 a = ° 2 o a “* Surgery: Whipple’s procedure “+ 15 line: 5-FU/LV, Dose 425 mg/m2 + 2"4 line: 5-FU/LV, Dose 2600 mg/m2/24hr “+ 3 line: Gemcitabine, Dose 1000 mg/m2/week “ OT-101- Liver mets/ Complete Resp
Slide 11: SIP Pipeline Built Around Sequencing
11 @ SIP© Pipeline Built Around Sequencing art ONCOTELIC~ Brain Cancer/ OT-101 + TMZ *Available through Expanded er Access Program together with Pancreatic Cancer/ OT-101* + ABK Widetrial — yo Melanoma/ OT-101* + CA4P: Necrosis Cell L WIDETRIAL **Partnered with NantCell, Dinona/Autotelic Bio Solid t
Slide 12: Management Team
af? ONCOTELIC Ti] )Management Team Vuong Trieu PhD coer ne Chief Executive Officer Odoraxis Go Aicorssor sorrento wr Fatih Uckun MD PhD 2A LP See Peeren NAME ics ONartkwest Chief Medical Officer cor Mixes Chulho Park PhD POOe tite d alyr Pharma Chief Technology Officer 7“ *="" Lit, 2) or Micorasor
Slide 13: World Class Medical Advisory Board
ONCOTELIC~ af? (TT y World Class Medical Advisory Board Dr. Stuart E. Siegel, M.D., received his B.A. and M.D. degrees from Boston University, pediatric training at the University of Minnesota, and pediatric oncology training at the National Cancer Institute. He has served asa Professor of Pediatric
Slide 14: Board of Directors
BPZ ONCOTELIC > @i y Board of Directors Vuong Trieu PhD- Chairman Former Executive Chairman/Interim CEO of Marina Biotech (OTCQB:ATRX), Director of Sorrento Therapeutics (Nasdaq:SRNE), Founder, Chairman, CEO of Igdrasol which was acquired by NantPharm. Coaguligand team under Phil Thorpe. *Coaguligan
Slide 15: Mateon/Oncotelic - Building The Next Generation Pharma
15 <i -—s «) ONCOTELIC~ Mateon/Oncotelic- (OTCQB:MATN)- Building The Next Generation Pharma are —@ — <i NAVIGATOR DATA PIPELINE Large Data Analytics Large Clinical Data High Value Pipeline Thank You
Slide 16: SIP Pipeline Built Around Sequencing
a af? ONcOTELIC T11) ) SIP© Pipeline Built Around Sequencing Preclinical Animal POC Phase 1 POC Brain Cancer/ OT-101 + TMZ y] *Available through Expanded Access Program together with Pancreatic Cancer/ OT-101* + ABX ( Widetrial yo WIDETRIAL **Partnered with NantCell, Dinona/Autotelic Bio tumors/ O1-
Slide 17: Explosion of Unstructured Data Requires AI for Business Transformation
EXPLOSION OF UNSTRUCTURED DATA REQUIRES Al FOR BUSINESS TRANSFORMATION VIDEO, IMAGES, AUDIO, NATURAL LANGUAGE, TV, EMAILS, SOCIAL MEDIA Unstructured data will account } unstructured | for more than 80% of the data collected by organizations IDC and EMC project that data will grow to 40 ZB by 2020. 1
Slide 18: Knowledge Synthesis Machine
KNOWLEDGE SYNTHESIS MACHINE ACTIONABLE DRUG DEVELOPMENT Unstructured Data Scientific Literature Patents Disease Symptoms Clinical Trial Structured Data Clinical Trials Cohort selection Patient tracker Reporting Synthesis >> Pharmaceutical Information <b PointR BRICK ii Patient & Provider Information
Slide 19: PointR Products
POINTR PRODUCTS BRICK 1.0 100W low footprint computer replaces racks of servers for data orchestration and coordination with data center BRICK 2.0 | Reduced Size hub of Al accelerator cluster for efficient localized cluster compute CUBE 1.0 » ! 30W fan-less compute hub of Al accelerator cluster conn
Slide 20: The Power Performance Disruption
THE POWER PERFORMANCE DISRUPTION Specs 6 Al Accelerators Cluster Processing 100 Watts Peak 9 Teraflops @16-bit PCle Fabric @10Gbps DMA Equals 11x Xeon 2790v4 CPU Dell r730 servers 1/100** power 1/20" price aM That's 11 Dell servers 20
Slide 21: The Power Performance Disruption
THE POWER PERFORMANCE DISRUPTION PointR BRICK 1.0 Can be used in any office environment Specs — BRICK 1.0 7.8 fps Inference 100 Watts Peak 9 Teraflops @16-bit PCle Fabric @10Gbps DMA Better than AC922 with V100 6.77 fps Inference 2200W Power 1/20 power IBM AC922 $53,000 price * 6x NV100 * 2xPPC9 1/1
Slide 22: The Small Pharma Opportunity
THE SMALL PHARMA OPPORTUNITY DISRUPTION IN A RAPIDLY GROWING MARKET $174 $98B $76B Accolade Growth —S Brand Name Pharmaceutical ae US Ae) BRASH 25. ae Revenue, US Market 2,904 Small Ph = 6 Large Pharma Bnd — 56% Market Share ) 2018 Market size estimates according to IBIS industry reports; value pote
Slide 23: Navigator Platform
Navigator Platform DATA FLOW THROUGH NAVIGATOR Al PLATFORM Match to Drug Live Trial Monitoring fh Post | i uF 7 i)
Slide 24: Blockchain for Drug Manufacturing
BLOCKCHAIN FOR DRUG MANUFACTURING Manufacturer
Slide 25: World Class Team in AI Deep Learning
WORLD CLASS TEAM IN Al DEEP LEARNING Saran Saund, CEO: Al Platforms Burcak Beser, CTO: ML/AI Algorithms, software, hardware Stephen Boesch, Data Science Engineering, ML/AI Mike Potts, Data Scientist, ML/Al Nagarjun Redla, Engineer, ML/Al, Matlab, Python Founder, CEO and GM of private and public comp
Slide 26: Relationships
RELATIONSHIPS Commercial, Academia and Open Source Companies HB Microsoft Technology ZA BI Azure & yy SA Open Source databricks docker MESOSPHERE Academia Opberkeley & McGill Stanford
Slide 27: Go-to-Market Partnership with IBM Launched at Supercomputing 2018
GO-TO-MARKET PARTNERSHIP WITH IBM LAUNCHED AT SUPERCOMPUTING 2018 ¢ PointR established a worldwide partnership with IBM including IBM Global Services which provides solutions to the Life Sciences vertical amongst others. ¢ IBM’s largest practice in Al is its Watson Health Services (1) with investmen
Mateon Therapeutics — Investor Presentation (September 2019) on 6ix